© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
Alopecia Areata: Emerging Data and Treatment Approaches
February 16th 2025
JAK inhibitors are being used widely and successfully to treat alopecia areata, and Amy McMichaels, MD, showcased data and also discussed patient communication.
The Great Atopic Dermatitis Treatment Debate: Biologics vs JAK Inhibitors
February 15th 2025
There really is no debate - it's all about individualizing treatment for the patient, but Drs Neal Bhatia and Raj Chovatiya went head to head at Midwinter Hawaii.
Key Advances in Oral Therapies for Psoriasis Unveiled at Winter Clinical Dermatology Conference 2025
February 15th 2025
April Armstrong, MD, discussed the latest data on apremilast, deucravacitinib, and emerging TYK2 and IL-23 inhibitors at Midwinter Hawaii.
60 Tips in 60 Minutes: Day 1 at the 2025 Midwinter Clinical Hawaii Dermatology Conference
February 15th 2025
The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.
The 2025 Winter Clinical Hawaii Dermatology Conference: Saturday Preview
February 14th 2025
The 2025 Winter Clinical Hawaii kicks off today with the first full day of educational sessions starting tomorrow, February 15 - here's what to look for.
5 Days in Hawaii: The Winter Clinical Hawaii Dermatology Conference
February 13th 2025
The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.
Dupilumab, Tezepelumab Gain Ground for Severe Asthma but Overall Biologic Adherence Rates Found Low: 2 Studies from 2025 AAAAI/WAO
February 12th 2025
AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.
Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk
February 12th 2025
AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.
AAAAI 2025: Omalizumab Shows Favorable Outcomes Versus Oral Immunotherapy in Multi‐Food Allergy Treatment
February 12th 2025
In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.
Expert Perspectives 2024: Nonsteroidal Topicals for Atopic Dermatitis with Mona Shahriari, MD
December 12th 2024
The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.